158 related articles for article (PubMed ID: 36143940)
1. Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.
Al-Saraireh YM; Alshammari FOFO; Satari AO; Al-Mahdy YS; Almuhaisen GH; Abu-Azzam OH; Uwais AN; Abufraijeh SM; Al-Kharabsheh AM; Al-Dalain SM; Al-Qtaitat A; Al-Tarawneh F; Al Shuneigat JM; Al-Sarayreh SA
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143940
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayra YM; Al-Saraireh RA; Al-Muhaisen GH; Al-Mahdy YS; Al-Kharabsheh AM; Abufraijeh SM; Alrawashdeh HM
Curr Oncol; 2021 Sep; 28(5):3573-3584. PubMed ID: 34590601
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Tarawneh F; Al-Sarayreh S; Almuhaisen GH; Satari AO; Al-Shuneigat J; Alrawashdeh HM
Breast Cancer (Dove Med Press); 2021; 13():565-574. PubMed ID: 34675653
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayreh S; Almuhaisen GH; Alnawaiseh N; Al-Shuneigat JM; Alrawashdeh HM
Onco Targets Ther; 2021; 14():5249-5260. PubMed ID: 34803385
[TBL] [Abstract][Full Text] [Related]
5. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
Downie D; McFadyen MC; Rooney PH; Cruickshank ME; Parkin DE; Miller ID; Telfer C; Melvin WT; Murray GI
Clin Cancer Res; 2005 Oct; 11(20):7369-75. PubMed ID: 16243809
[TBL] [Abstract][Full Text] [Related]
6. Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues.
Al-Saraireh YM; Alboaisa NS; Alrawashdeh HM; Hamdan O; Al-Sarayreh S; Al-Shuneigat JM; Nofal MN
Ecancermedicalscience; 2020; 14():1114. PubMed ID: 33144882
[TBL] [Abstract][Full Text] [Related]
7. 1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1.
Qin H; Zhou Y; Liu H; Yuan Y; Guo Q; Yuan M; Xi T; Zhang Y
Environ Toxicol; 2024 Mar; 39(3):1505-1520. PubMed ID: 37994574
[TBL] [Abstract][Full Text] [Related]
8. CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer.
Yang X; Hutter M; Goh WWB; Bureik M
Curr Pharm Des; 2017; 23(14):2060-2064. PubMed ID: 28176668
[TBL] [Abstract][Full Text] [Related]
9. Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in
McDonald MG; Ray S; Amorosi CJ; Sitko KA; Kowalski JP; Paco L; Nath A; Gallis B; Totah RA; Dunham MJ; Fowler DM; Rettie AE
Drug Metab Dispos; 2017 Dec; 45(12):1364-1371. PubMed ID: 29018033
[TBL] [Abstract][Full Text] [Related]
10. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayreh S; Almuhaisen GH; Alnawaiseh N; Al Shuneigat JM; Alrawashdeh HM
Sci Rep; 2021 Mar; 11(1):5581. PubMed ID: 33692504
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.
Yu W; Chai H; Li Y; Zhao H; Xie X; Zheng H; Wang C; Wang X; Yang G; Cai X; Falck JR; Yang J
Toxicol Appl Pharmacol; 2012 Oct; 264(1):73-83. PubMed ID: 22841774
[TBL] [Abstract][Full Text] [Related]
12. Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1.
Du W; Machalz D; Yan Q; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2020 Apr; 174():113850. PubMed ID: 32044355
[TBL] [Abstract][Full Text] [Related]
13. There and Back Again: A Perspective on 20 Years of CYP4Z1.
Kowalski JP; Rettie AE
Drug Metab Dispos; 2024 May; 52(6):498-507. PubMed ID: 38604728
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Immunobiology; 2022 Mar; 227(2):152174. PubMed ID: 34999392
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.
Khayeka-Wandabwa C; Zhao J; Pathak JL; Wu H; Bureik M
Breast Cancer Res Treat; 2022 Jan; 191(2):319-326. PubMed ID: 34725776
[TBL] [Abstract][Full Text] [Related]
16. Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
Kowalski JP; McDonald MG; Pelletier RD; Hanenberg H; Wiek C; Rettie AE
J Med Chem; 2020 May; 63(9):4824-4836. PubMed ID: 32302132
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.
Rieger MA; Ebner R; Bell DR; Kiessling A; Rohayem J; Schmitz M; Temme A; Rieber EP; Weigle B
Cancer Res; 2004 Apr; 64(7):2357-64. PubMed ID: 15059886
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
Machalz D; Li H; Du W; Sharma S; Liu S; Bureik M; Wolber G
Eur J Med Chem; 2021 Apr; 215():113255. PubMed ID: 33611185
[TBL] [Abstract][Full Text] [Related]
19. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast.
Yan Q; Machalz D; Zöllner A; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2017 Dec; 146():174-187. PubMed ID: 28951277
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
